摘要
目的:探讨支气管哮喘患儿应用丙酸氟替卡松气雾剂治疗的效果,并分析其对血清皮质醇水平的影响。方法:随机抽取本院2014年5月-2015年9月收治的支气管哮喘患儿124例作观察组,该时间段于本院行儿童健康体检者120例作对照组,探讨哮喘患儿应用丙酸氟替卡松气雾剂的治疗效果,并通过对照研究的方式,探讨其对血清皮质醇水平的影响。结果:观察组治疗过程中血清皮质醇水平呈现出稍微降低的趋势,但是各个时间段与对照组比较,差异均无统计学意义(P>0.05),并且观察组患儿治疗12个月与治疗前、治疗6个月比较,差异均无统计学意义(P>0.05),观察组临床总有效率为93.55%(116/124)。观察组治疗12个月后PEF、FEV1水平均显著高于治疗前(P<0.05);观察组治疗12个月后日间、夜间症状评分均下降,均低于治疗前(P<0.05)。结论:哮喘患儿应用丙酸氟替卡松气雾剂治疗,可取得较为理想的临床效果,并且不会对患儿血清皮质醇水平造成影响,具有较高的临床应用价值。
Objective: To explore the effect of Fluticasone Propionate Aerosol in children with bronchial asthma treatment, and analyze its influence on the serum cortisol level,Method: 124 children with bronchial asthma and who accepted treatments in our hospital from May 2014 to September 2015 were randomly selected as the observation group, and 120 cases of children's health examination in our hospital in this period were selected as the control group.Then, the effect of Fluticasone Propionate Aerosol in treatment of children with asthma were discussed, and the influence on the serum cortisol level were discussed by the means of the control study.Result: In the observation group, the serum cortisol level showed slightly decreasing trend in the course of treatment, but there were no differences between each time period compared with the control group ( P〉0.05 ), and after treatment for 12 months in the observation group were compared with before treatment and after treatment 6 months, there were no statistically significant differences ( P〉0.05 ), the observation group total effective rate was 93.55% ( 116/124 ) .In the observation group, the level of PEF and FEV1 after treatment 12 months were significantly higher than those before treatment (P〈0.05) .In the observation group, the daytime and nighttime symptom scores after treatment 12 months were decreased, and which were lower than those before treatment ( P〈0.05 ) .Conclusion: The application of Fluticasone Propionate Aerosol asthma treatment, clinical efficacy can be achieved ideal, and does not affect the serum cortisol levels in children, with a high clinical value.
出处
《中国医学创新》
CAS
2016年第36期11-14,共4页
Medical Innovation of China
基金
湖北省卫生厅重大项目(M01564)